Levofloxacina Kabi (Levofloxacin Hemihydrate)

Levofloxacina Kabi, a fluoroquinolone antibiotic, is indicated for several serious bacterial infections that require intravenous therapy in hospital settings.

• Severe community‑acquired pneumonia: achieves bacterial eradication and clinical improvement in hospitalized adults.
• Complicated urinary tract infections: provides effective treatment of resistant Gram‑negative pathogens in the urinary system.
• Intra‑abdominal infections: penetrates peritoneal tissues to control polymicrobial infections following surgery.
• Skin and soft‑tissue infections: reduces bacterial load in cellulitis, abscesses and wound infections.
• Hospital‑acquired pneumonia: delivers high lung concentrations to treat multidrug‑resistant organisms.

• Levofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription and repair. By binding to the quinolone‑binding region of these enzymes, it prevents the resealing of DNA breaks, leading to accumulation of double‑strand breaks and bacterial cell death. The drug exhibits concentration‑dependent bactericidal activity against a broad spectrum of Gram‑positive and Gram‑negative organisms clinically.

Levofloxacina Kabi may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

• Nausea: mild to moderate nausea may occur, often transient and self‑limiting.
• Diarrhea: watery diarrhea can develop, usually resolves after therapy completion.
• Headache: headache of varying intensity may be reported during treatment.
• Rash: maculopapular skin rash may appear, requiring monitoring for progression.

Serious or Rare Side Effects

• Tendon rupture: increased risk of Achilles or other tendon rupture, especially in elderly or those on corticosteroids; discontinue if pain develops.
• QT prolongation: can prolong cardiac QT interval leading to torsades de pointes; monitor ECG in at‑risk patients.
• Clostridioides difficile infection: may cause severe colitis with watery diarrhea and abdominal pain; requires prompt treatment.

When using Levofloxacina Kabi, several precautions should be observed to minimize risks.

• Renal function: adjust dosing in patients with impaired renal clearance and monitor serum creatinine.
• QT interval: avoid use in patients with known QT prolongation or concurrent QT‑prolonging drugs.
• Tendon health: discontinue therapy at first sign of tendon pain or inflammation to prevent rupture.
• C. difficile risk: monitor for severe diarrhea, especially after prolonged therapy.
• Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levofloxacina Kabi can interact with other medicines; awareness of major and moderate interactions helps ensure safe use.

Major Interactions (Avoid)

• Antacids containing aluminum or magnesium: reduce levofloxacin absorption; separate administration by at least 2 hours.
• Warfarin: may increase anticoagulant effect and INR; monitor coagulation parameters closely.
• Theophylline: levofloxacin can raise theophylline levels, increasing risk of toxicity; monitor serum concentrations.

Moderate Interactions (Monitor Closely)

• Corticosteroids: combined use raises risk of tendon rupture; advise patients to report musculoskeletal pain.
• Oral contraceptives: may reduce hormonal efficacy; recommend additional non‑hormonal contraception.